Last reviewed · How we verify
NCT05501405: FERmarkers
Brain and Oculometric Markers of Emotional Facial Expression Recognition Deficits
NA trial testing Electroencephalogram and eye-tracking recordings in Autism in 14 participants. Terminated before completion.
25 April 2025
Quick facts
| Lead sponsor | Hôpital le Vinatier |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 14 |
| Start date | 30 March 2022 |
| Primary completion | 25 April 2025 |
| Estimated completion | 25 April 2025 |
| Sites | 1 location across France |
Drugs / interventions tested
- Electroencephalogram and eye-tracking recordings
Conditions studied
- Autism — all drugs for Autism →
- Psychotic Disorders — all drugs for Psychotic Disorders →
Sponsor
Hôpital le Vinatier — full company profile →
Who can join
Adults 10 to 50, any sex, with Autism or Psychotic Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Disorders in the recognition of emotional facial expressions are part of the social cognition disorders described in several diseases. They are notably present in a quasi-systematic way in diseases associated with socio-emotional behavior disorders, such as schizophrenia and autism. They are also found in some genetic syndromes with atypical neurodevelopment. In previous studies, the investigators adopted the FPVS-EEG approach to investigate facial emotion discrimination abilities in typical and atypical developing populations. the investigatorshave shown that, in typical adults, the neural response to facial expressions emerges as emotional intensity parametrically increases. A time-domain analysis revealed three components, with the first two increasing linearly with expressive intensity, and the third (beyond 300 ms) showing categorical sensitivity to increasing expressive intensity. The investigators have already successfully extended this approach to the investigation of patients, such as those with 22q11.2 syndrome. The brain response to facial expression was reduced by approximately 36% in these patients, revealing impaired visual coding of emotional facial signals. In this study, response amplitude was associated with positive symptom severity, indicating a potential endophenotype for psychosis risk. Here, the investigators study the implementation of high-level processes and the top-down effect it should have on the response of occipitotemporal regions to identify altered brain markers in schizophrenic patients, but also in other populations with expression recognition deficits (autistic, 22q11.2, in particular). The implementation of compensatory strategies that should result in an increased exploration of the lower part of the face at the oculometric level will also be studied.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05501405
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Autism
Currently open trials in the same condition.
- NCT07367256 — Using Virtual Reality to Improve Emotion Understanding in Children With Autism · NA · recruiting
- NCT06853665 — The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine · Phase 4 · recruiting
- NCT06523387 — Online Pivotal Response Treatment Training in Autism Spectrum Disorder · NA · recruiting
- NCT07304440 — Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study · Phase 1, PHASE2 · recruiting
- NCT07403396 — Static Balance Assessment in Children With ASD Using VRRS · recruiting
Other Hôpital le Vinatier trials
Trials by the same sponsor.
- NCT07428200 — Characterization of the Neural Bases of Mental Imagery in Individuals With Borderline Personality Disorder: An EEG Study · NA · not yet recruiting
- NCT07384819 — Duration of Moment in Autism · NA · not yet recruiting
- NCT06284382 — Interaction Between Early Trauma and Odor-induced Dopamine Release · NA · not yet recruiting
- NCT07119671 — Peer-aid and Hope Box · NA · not yet recruiting
- NCT06869915 — Homelessness and Prevalence of Neurodevelopmental Disorders · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05501405 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hôpital le Vinatier
- Last refreshed: 3 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05501405.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing